Will Multiple Myeloma treatment make me infertile

Multiple Myeloma Treatment and Fertility: What You Should Know

This is an important question, and I'm glad you're thinking ahead about this. Let me explain what the evidence shows about myeloma treatments and fertility.

The Short Answer

Some multiple myeloma treatments can affect fertility, but it depends on which specific drugs you receive and your individual situation. The good news is that fertility preservation options exist, and this is something you should discuss with your care team before starting treatment.

How Different Myeloma Treatments Affect Fertility

According to the NCCN Guidelines for Patients: Multiple Myeloma, treatment typically involves combinations of several drug types:

Chemotherapy Drugs (Higher Risk)

Chemotherapy drugs like cyclophosphamide (Cytoxan) and bendamustine (Treanda) can damage sperm production in men and affect egg quality or ovarian function in women. These drugs work by targeting rapidly dividing cells—which includes both cancer cells and reproductive cells.

• In men: Can cause temporary or permanent reduction in sperm count
• In women: Can damage eggs or cause premature ovarian failure (early menopause)

Targeted Therapy Drugs (Lower Risk)

Drugs like proteasome inhibitors (bortezomib/Velcade, carfilzomib/Kyprolis) and immunomodulators (lenalidomide/Revlimid, pomalidomide/Pomalyst) have less documented impact on fertility, though some carry risks:

• Lenalidomide and pomalidomide are known to cause birth defects and cannot be used during pregnancy (these require strict contraception during treatment)
• Other targeted therapies have limited fertility data

Monoclonal Antibodies and Newer Therapies (Variable)

Drugs like daratumumab (Darzalex) and CAR T-cell therapy have less established fertility effects, but long-term data is still being collected.

Corticosteroids (Lower Risk)

These are used as part of combination therapy and generally have minimal direct impact on fertility at treatment doses.

Important Factors That Affect Your Risk

Your fertility risk depends on:

1. Which specific drugs you receive (your exact treatment combination)
2. Doses used (higher doses = higher risk)
3. Duration of treatment (longer treatment = more exposure)
4. Your age (younger patients may recover fertility better)
5. Your sex (men and women have different risks and recovery patterns)
6. Whether you've had previous cancer treatments

What You Can Do NOW

Before starting treatment, ask your oncology team these specific questions:

1. "Which specific drugs will be in my treatment plan, and which ones carry fertility risks?"
2. "Should I consider fertility preservation before starting treatment?" (This is especially important if chemotherapy is part of your plan)
3. "For men: Can I bank sperm before treatment starts?" (This is often possible and relatively simple)
4. "For women: Are there egg freezing or embryo preservation options I should consider?"
5. "Will my treatment affect my ability to have children in the future, and if so, is it temporary or permanent?"
6. "Are there alternative drug combinations that might have lower fertility risks for me?"

Fertility Preservation Options

If fertility is important to you, options may include:

• Sperm banking (for men) - can be done quickly before treatment
• Egg freezing (for women) - takes 2-4 weeks, may delay treatment slightly
• Embryo freezing (if you have a partner) - also takes 2-4 weeks
• Ovarian tissue freezing (experimental but increasingly available)

These should be discussed with a fertility specialist before starting myeloma treatment.

During and After Treatment

• During treatment: Use reliable contraception if you can become pregnant (some myeloma drugs cause birth defects)
• After treatment: Fertility may recover over time, especially if you didn't receive high-dose chemotherapy
• Monitoring: Your care team can check fertility markers during follow-up visits

The Bottom Line

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

The key is to have this conversation with your oncologist before treatment starts. According to the NCCN Guidelines, cancer care should be individualized to your situation, and fertility preservation is an important part of that discussion. Many myeloma specialists are experienced in helping patients navigate these concerns and can work with fertility specialists if needed.

Don't hesitate to ask—this is a legitimate medical concern that deserves attention as part of your overall treatment planning.